2026– date –
-
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highlighting the paradigm shift triggered by Enhertu and the evolving player landscape. In Pa... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, discussed the impact of Enhertu, and looked at how pharma, biotech, and investors are rea... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Multi-billion-dollar acquisitions, mega licensing deals, capacity expansions for ADC manufacturing, and the... -
The Hidden Pitfall of AI Drug Discovery: The Quiet Wall of Reproducibility in Scientific Literature
Introduction: Past Knowledge Is Now the Starting Point of Future Drug Discovery AI-driven drug discovery has become an increasingly central part of modern pharmaceutical R&D. The speed at which novel drug candidates can be identified... -
2026 Global Biotech & Pharma Outlook (Part 2) — Where Technological Progress Is Taking Shape —
Happy New Year. In Part 2, we turn our focus to technological domains where steady and meaningful progress is expected beyond 2026. Rather than highlighting short-lived trends, this article explores areas grounded in scientific necessity... -
2026 Global Biotech & Pharma Outlook (Part 1) — Where Science and Innovation Are Heading —
Happy New Year. At the beginning of a new year, it is often useful to step back from daily headlines and reflect on broader directions. In this article, we explore the global outlook for the biotechnology and pharmaceutical industries as...
